China: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

USITC Will Investigate State Support And Pricing Practices By Chinese Biotechnology Firms

The U.S. International Trade Commission (USITC) announced on February 26, 2026, that it is undertaking a factfinding investigation to examine Chinese state support and pricing...

China Healthcare

BC

Bergeson & Campbell

China Life Sciences: 2025 Year In Review

2025 was a year of notable developments for China's life sciences industry, marked by significant revisions to major legislation and regulations.

China Healthcare

AP

Arnold & Porter

开启直播电商合规新纪元 |《直播电商监督管理办法》重点解读（下）

日前，市场监管总局、国家网信办联合发布...

China Media & IT

FP

Fangda Partners

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

On January 16, 2026, the State Council of the People's Republic of China promulgated the revised Regulations for the Implementation of the Drug Administration Law (the "Implementing Regulations")...

China Healthcare

FP

Fangda Partners

China Newsletter | Q3 2025/Issue No. 65

GT

Greenberg Traurig, LLP

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Tips For Pharmaceutical Use Claims

CT

Chang Tsi & Partners

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

China Released Draft Medical Device Law For Comments

China Healthcare

HK

Han Kun Law Offices

Understanding China's Pharmaceutical Patent Linkage System: Framework And Case Overview (Part 1)

CT

Chang Tsi & Partners

生物医药领域符合WIPO标准ST.26的序列表制作经验

CP

CCPIT Patent & Trademark Law Office

China Life Sciences Compliance Update: Insurance Fraud Enforcement Campaign And New Ethical Code For HCPs

China Healthcare

AP

Arnold & Porter

China Life Sciences Compliance Update: Kickback And Third-Party Case Study

China Healthcare

AP

Arnold & Porter

Understanding The EU's International Procurement Instrument

China Government

CM

Crowell & Moring LLP

规行矩步，进而有为——中国私募基金行业年度观察报告（2025）

China Commercial

FP

Fangda Partners

The Patent Term Compensation And Protection Scope In The Compensated Period For Drug Invention Patents

AC

AFD China

The Latest On China's Policy Re Crypto Currencies And RWA Tokenization

China Technology

FP

Fangda Partners

海上货物运输中货物短量的认定 -- 以一起木材运输案[1]为视角

China Transport

JT

Beijing Jincheng Tongda & Neal Law Firm

英国毕业生签证最新要求和新规解析｜UK Graduate Visa Rules & Requirements (Video)

China Immigration

L

Latitude Law

汉坤 • 观点 | 《药品管理法实施条例》（修订草案）重点快评

2022年5月9日，国家药监局发布《药品管理法实施条例（修订草案征求意见稿）》（简称"《征求意见稿》"），向社会公开征求意见，征求意见反馈截止

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 中国药品年度报告制度简析

2022年4月11日，国家药品监督管理局（" 国家药监局"）发布了《药品年度报告管理规定》以及相应的报告模板（以下合称" 《年报规定》"）...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 简评新版《医疗器械临床试验质量管理规范（GCP）》

自国务院于2015年发布《关于改革药品医疗器械审评审批制度的意见》（国发〔2015〕44号）并启动药品医疗器械审评审批制度改革工作以来，我国不断߾

China Healthcare

HK

Han Kun Law Offices

Compliance Highlights And Strategies In High-Risk Clinical Research Landscape

近期，部分医药行业动态引发了广泛关注，临床研究合规问题再次成为众多企业重点讨论的话题。

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Settle The Dust Or Let The Bullets Fly: Biden Administration Signs Executive Order On Promoting Biotechnology And Biomanufacturing Innovation

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

"不竞争条款（Non-Compete Clause）"是License-in/out交易中保障技术价值、

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

License-in/out transactions have become a key strategic approach for innovative drug and medical device (including medical aesthetics) companies to expedite the research and development of the products and expand market presence.

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

On March 28, 2023, the Hainan Provincial People's Government officially issued the "Regulations on the Administration of Imported Drugs and Medical Devices Urgently Needed in Clinical Needs...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

On March 24, 2023, the State Administration for Market Regulation publicly issued the "Measures for the Administration of Internet Advertising" (the "Measures")...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Blockbuster Debut: Interpretation Of The Key Points Of The Implementation Rules Of The Regulations On The Management Of Human Genetic Resources

On June 1, 2023, the Ministry of Science and Technology of our country (hereinafter referred to as the "Ministry of Science and Technology") officially issued the Implementation...

China Healthcare

HK

Han Kun Law Offices

观点 | 生命科学行业License-in/out合同争议要点分析（四）：首付款是否可能退回？

从被许可方的角度，虽然在商业上达成一致的前提下，双方设定首付款可退还的特定条件存在一定可能性，但是实践中此类条款谈判难度较高A

China Commercial

HK

Han Kun Law Offices

药企出海新热点：管线分拆"SON"模式的实践解读

近期，医药行业正掀起一股"管线分拆项目"（"Spin off-NewCo"，或称"SON"模式）的热潮。短短两个月，笔者即接手了近十起管线分拆项目。

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023

Recently, a nationwide campaign to combat corruption in the pharmaceutical sector has been underway in full swing, attracting widespread attention from the industry...

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | CAR-T/NK Regulatory Decisions — Interpreting The "Guidelines For Somatic Cell Clinical Research (Trial)"

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 从药械产品全生命周期视角解读License-in/out许可交易项目合作条款要点

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 企业或需自设伦理委员会：《科技伦理审查办法（试行）》正式出台

China Healthcare

HK

Han Kun Law Offices

Han Kun • Viewpoint | Interpretation Of The "Annual Report On The Progress Of Clinical Trials For New Drug Registration In China (2022)"

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | 2023 Life Sciences Regulatory Compliance Annual Summary

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Quick Review Of The New Regulations: Interpret The Latest Questions And Answers Of The Ministry Of Science And Technology

China Healthcare

HK

Han Kun Law Offices

Han Kun • Quick Comment | Is The Transmission Of Cross-border Genomic Data Between China And The United States Blocked? Biden Data Executive Order Quick Review

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Analysis Of Key Points Of License-In/out Contract Disputes In The Life Sciences Industry (1): Joint Steering Committee, Reasonable Commercial Efforts, Confidentiality Obligations

China Healthcare

HK

Han Kun Law Offices

Hankun • Quick Comment | The Regulations On Human Genetic Resources Management Are Revised Again

China Healthcare

HK

Han Kun Law Offices

The New Regulations On Medical Aesthetics Came Into Effect Today - The Supervision Of Radio Frequency Beauty Devices Such As Thermage And Heatlifter Has Been Upgraded

China Healthcare

HK

Han Kun Law Offices

More Than 60 Innovative Drugs Were Approved: Interpretation Of The Highlights Of The 2022-2023 China Drug Review Report

China Healthcare

HK

Han Kun Law Offices

2022-2023 China Medical Device License-In/Out Project Core Clause Data Analysis

China Healthcare

HK

Han Kun Law Offices

61款创新医疗器械获批：2023年度中国医疗器械注册工作报告亮点解读

China Healthcare

HK

Han Kun Law Offices

Overview: 2022-2023 China Drug & Medical Device Annual Report

China Healthcare

HK

Han Kun Law Offices

Top 10 Traps To Avoid: Navigating China's HGR Applications

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More